Latest Insider Transactions at Amylyx Pharmaceuticals, Inc. (AMLX)
This section provides a real-time view of insider transactions for Amylyx Pharmaceuticals, Inc. (AMLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Amylyx Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Amylyx Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 17
2023
|
Patrick D Yeramian Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,579
+8.42%
|
$148,737
$3.63 P/Share
|
|
Mar 29
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
29,048
-0.41%
|
$871,440
$30.45 P/Share
|
|
Mar 28
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-1.4%
|
$3,000,000
$30.37 P/Share
|
|
Mar 27
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
60,964
-0.43%
|
$1,828,920
$30.53 P/Share
|
|
Mar 21
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
63,448
-0.44%
|
$1,966,888
$31.93 P/Share
|
|
Mar 16
2023
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+1.73%
|
-
|
|
Mar 16
2023
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-1.73%
|
$3,200,000
$32.16 P/Share
|
|
Mar 16
2023
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,333
+24.75%
|
-
|
|
Mar 16
2023
|
Patrick D Yeramian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,167
+5.46%
|
-
|
|
Mar 16
2023
|
Patrick D Yeramian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
54,627
-13.57%
|
$1,748,064
$32.14 P/Share
|
|
Mar 16
2023
|
George M Milne Jr |
SELL
Open market or private sale
|
Direct |
35,000
-1.96%
|
$1,120,000
$32.16 P/Share
|
|
Mar 16
2023
|
Margaret Olinger Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,333
+7.3%
|
-
|
|
Mar 16
2023
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+1.73%
|
-
|
|
Mar 16
2023
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
100,000
-1.73%
|
$3,200,000
$32.15 P/Share
|
|
Mar 16
2023
|
Karen Firestone |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$31,000
$31.99 P/Share
|
|
Mar 16
2023
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,667
+48.32%
|
-
|
|
Mar 16
2023
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,500
-71.79%
|
$1,040,000
$32.16 P/Share
|
|
Mar 16
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
9,122
-0.13%
|
$291,904
$32.55 P/Share
|
|
Mar 15
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
150,000
-1.02%
|
$4,950,000
$33.4 P/Share
|
|
Mar 14
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
70,714
-0.95%
|
$2,404,276
$34.54 P/Share
|
|
Mar 02
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.66%
|
$1,650,000
$33.75 P/Share
|
|
Feb 24
2023
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,586
-8.75%
|
$121,924
$34.49 P/Share
|
|
Feb 23
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-0.33%
|
$1,750,000
$35.9 P/Share
|
|
Feb 22
2023
|
Morningside Venture Investments LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-0.33%
|
$3,500,000
$35.57 P/Share
|
|
Jan 06
2023
|
James M Frates Chief Financial Officer |
BUY
Open market or private sale
|
Direct |
2,658
+3.68%
|
$95,688
$36.44 P/Share
|
|
Jan 06
2023
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Open market or private sale
|
Direct |
5,968
+0.1%
|
$214,848
$36.44 P/Share
|
|
Jan 06
2023
|
Patrick D Yeramian Chief Medical Officer |
BUY
Open market or private sale
|
Direct |
2,034
+0.49%
|
$73,224
$36.44 P/Share
|
|
Jan 06
2023
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Open market or private sale
|
Direct |
5,968
+0.1%
|
$214,848
$36.44 P/Share
|
|
Jan 06
2023
|
Margaret Olinger Chief Commercial Officer |
BUY
Open market or private sale
|
Direct |
2,403
+0.56%
|
$86,508
$36.44 P/Share
|
|
Dec 30
2022
|
James M Frates Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.0%
|
$30,000
$6.88 P/Share
|
|
Sep 09
2022
|
Viking Global Investors LP |
SELL
Open market or private sale
|
Indirect |
700,000
-3.7%
|
$21,000,000
$30.74 P/Share
|
|
Sep 08
2022
|
Viking Global Investors LP |
SELL
Open market or private sale
|
Indirect |
700,000
-2.03%
|
$20,300,000
$29.48 P/Share
|
|
Jul 06
2022
|
Invest 1 B.V. Als > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
60,609
-0.26%
|
$1,212,180
$20.97 P/Share
|
|
May 05
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
334,520
+10.35%
|
$0
$0.37 P/Share
|
|
May 05
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
334,520
+10.35%
|
$0
$0.37 P/Share
|
|
Feb 22
2022
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+50.0%
|
-
|
|
Jan 11
2022
|
Invest 1 B.V. Als > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,955,889
+47.38%
|
-
|
|
Jan 11
2022
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
263,158
+2.41%
|
$5,000,002
$19.0 P/Share
|
|
Jan 11
2022
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
10,415,650
+50.0%
|
-
|
|
Jan 11
2022
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
2,300,000
+50.0%
|
$43,700,000
$19.0 P/Share
|
|
Jan 11
2022
|
Viking Global Investors LP |
BUY
Conversion of derivative security
|
Indirect |
4,870,536
+50.0%
|
-
|
|
Jan 06
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+2.84%
|
-
|
|
Jan 06
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,870
+0.2%
|
-
|
|
Jan 06
2022
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+50.0%
|
-
|
|
Jan 06
2022
|
Margaret Olinger Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
6,842
+3.06%
|
$129,998
$19.0 P/Share
|
|
Jan 06
2022
|
Margaret Olinger Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,333
+11.89%
|
-
|
|
Jan 06
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+2.84%
|
-
|
|
Jan 06
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,870
+0.2%
|
-
|
|
Jan 06
2022
|
George M Milne Jr |
BUY
Open market or private purchase
|
Direct |
26,315
+10.62%
|
$499,985
$19.0 P/Share
|
|
Jan 06
2022
|
Patrick D Yeramian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,333
+12.07%
|
-
|